Novo Nordisk's Valuation Reset: The Market Is Paying for What It Gets, Not What It Once Hoped For
Published on 08/07/2026 at 14:51 | Redaktion boerse-global.de
There is a moment in every growth story when the market stops pricing in promise and starts pricing in proof. For Novo Nordisk, that moment appears to have arrived. The Danish pharmaceutical giant closed Friday at €40.62, up 1.74 percent on the day, yet still roughly 26 percent below its 52-week high. The stock's slide is not a blip — it is the visible arithmetic of a company whose pipeline has stumbled just as its fiercest rival has surged ahead.
The Competitive Scoreboard Has Shifted
The most striking number in the current debate is not Novo Nordisk's own revenue growth — it is the market share held by Eli Lilly. In the US GLP-1 business, Lilly has expanded its share to 60.9 percent, while Novo Nordisk has slipped to 38.8 percent. That is not a momentary snapshot but a structural shift that has been building for quarters.
The valuation gap tells the same story from a different angle. Novo Nordisk trades at a price-to-earnings ratio of 11, while Eli Lilly commands 33. Investors are not merely punishing one company; they are re-rating an entire competitive landscape. The days of Novo Nordisk's "invincibility premium" are over, replaced by a more sober, value-oriented assessment.
A Quarter of Contradictions
The second-quarter 2026 results capture the tension neatly. On an adjusted basis, revenue rose 7 percent in currency-adjusted terms, while adjusted operating profit climbed 11 percent. Management responded by lifting full-year guidance to a range of 0 to minus 6 percent at constant exchange rates, citing stronger expectations for its GLP-1 products.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
But the same quarter carried a heavy counterweight: non-cash impairment charges of 6.3 billion Danish kroner on intangible pipeline assets, with 4.0 billion kroner tied to the drug candidate monlunabant alone. The message embedded in those write-downs is unambiguous — the pipeline is not delivering at the pace the share price once assumed.
The most consequential setback came in late July, when Novo Nordisk released results from the ZEUS study of ziltivekimab. In patients with atherosclerotic cardiovascular disease, chronic kidney disease, and inflammatory markers, the drug failed to reduce major cardiovascular events versus placebo. The hazard ratio came in at 0.99, with a confidence interval spanning 0.88 to 1.11 — a clearly missed primary endpoint, not a borderline case. Management insists the full-year adjusted operating profit outlook is unaffected, but has flagged another non-cash impairment for the third quarter of 2026. Two further ziltivekimab trials, HERMES in heart failure and ARTEMIS following acute myocardial infarction, remain ongoing, with results expected only in the first half of 2027. Until then, a large question mark hangs over a compound that clearly absorbed substantial investment.
Wegovy's Pill Keeps the Engine Running
Against that backdrop, the commercial franchise continues to perform. The Wegovy pill has surpassed 5 million prescriptions since launch, and the rollout of the higher-dose 7.2-milligram version is underway. For the week ending July 17, Novo Nordisk reported more than 265,000 weekly pill prescriptions in the US alone, claiming market leadership in new patient starts among approved obesity treatments.
Yet even the flagship shows hairline cracks. Quarterly sales of the pill reached 3.218 billion Danish kroner, marginally below the analyst consensus of 3.267 billion. A small miss, but symbolically significant: even the growth engine is not firing on all cylinders right now. The CagriSema combination therapy, once touted as the next major growth driver, also failed to meet its targets in the REDEFINE-4 study.
Capital Returns and Legal Wins
Novo Nordisk is not behaving like a company in retreat. The board declared an interim dividend of 3.75 Danish kroner per share, with an ex-date of August 14 and payment on August 18. A share buyback program for B-shares, launched May 6 with a volume of up to 11.2 billion kroner, is set to run until early February 2027. By early August, roughly 27 million B-shares had been repurchased at an average price of 278.35 kroner, worth around 7.5 billion kroner. Deploying that much capital into one's own stock while the pipeline stumbles sends a clear signal: management considers the current price undervalued.
On the legal front, the company secured a victory on Wednesday when a district court in The Hague issued a preliminary injunction barring Ceban Ziekenhuisfarmacie from selling a compounded semaglutide nasal spray that infringed Novo Nordisk's supplementary protection certificate. Ceban must remove product listings, disclose its supply chain, and cover Novo Nordisk's legal costs. The ruling does not change the big picture, but it underscores how contested the GLP-1 field has become — and how aggressively the company defends its intellectual property. The certificate extends semaglutide exclusivity until March 2031, with the base patent for Ozempic expiring between 2031 and 2032.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
A Strategy of Diversification
Chief executive Mike Doustdar is increasingly betting on oral therapies, arguing that tablets could come to dominate the weight-loss business. The company is also advancing a collaboration with Vivani Medical on a semaglutide implant that has been in development since July 2026. Novo Nordisk is not merely defending its turf — it is actively searching for the next pillar of growth.
The Technical Picture
The stock's technical indicators suggest a market searching for a floor without having found one. The relative strength index sits at 41.5, indicating neither overbought nor deeply oversold conditions. Annualized 30-day volatility of nearly 40 percent makes clear that calm is not on the menu. The 52-week low of €30.25, roughly 32 percent below current levels, serves as a potential support floor, while the January high of €54.86 appears out of reach for now.
The Bottom Line
Last year, Novo Nordisk generated over 72 billion Danish kroner in profit — it remains a formidable cash-flow machine. What it has lost is the market's willingness to pay a premium for invulnerability. For private investors, the stock has transitioned from a momentum play into a value-oriented pharmaceutical investment. The raised guidance, the real capital returns, and Wegovy's continued growth provide genuine operational substance. But the pipeline setbacks at ziltivekimab and monlunabant will keep weighing on the valuation until HERMES and ARTEMIS deliver clarity in 2027. Buying Novo Nordisk today means buying the core business — the pipeline is a bet with an open outcome, and the market is no longer extending credit for it in advance.
Ad
Novo Nordisk Stock: New Analysis - 7 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
